Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL8 shRNA
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
IL8 shRNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of Interleukin-8 (IL8/CXCL8). IL8 is a pro-inflammatory chemokine that plays a critical role in the tumor microenvironment by promoting the proliferation, migration, and survival of cancer cells, particularly colon cancer-initiating cells (CCICs). By delivering short hairpin RNA sequences that target IL8 mRNA for degradation, this approach aims to inhibit the autocrine and paracrine signaling pathways that drive tumorigenicity and the progression from chronic inflammation (such as ulcerative colitis) to colitis-associated cancer. Preclinical studies have demonstrated that IL8 knockdown significantly reduces tumor growth in xenograft models.
- Other names
- Interleukin-8 short hairpin RNAInterleukin8 short hairpin RNAInterleukin 8 short hairpin RNACXCL8 shRNACXCL-8 shRNACXCL 8 shRNA
02
Targets
Interleukin-8 messenger RNA (CXCL8 mRNA)
Beyond the preview
Go deeper on IL8 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL8 shRNA.